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http://www.diagnosticpathology.org/content/7/1/159RESEARCH Open AccessReduced expression of microRNA-100 confers
unfavorable prognosis in patients with bladder
cancer
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Wei Wu2 and Qingwen Li1*Abstract
Objective: MicroRNA-100 (miR-100) has been demonstrated to be downregulated in bladder cancer tissues, and
enforced expression of this miRNA may inhibit cell growth and colony formation of human bladder cancer 5637
cells in vitro. However, the clinical significance of miR-100 in human bladder cancer has not yet been elucidated.
Thus, the aim of this study was to investigate the diagnostic and prognostic values of miR-100 in this disease.
Methods: Expression levels of miR-100 in 126 pairs of bladder cancer and adjacent normal tissues were detected
by TaqMan real-time quantitative RT-PCR assay. In order to determine its prognostic value, overall survival (OS) and
progression-free survival (PFS) were evaluated using the Kaplan-Meier method, and multivariate analysis was
performed using the Cox proportional hazard analysis.
Results: Expression levels of miR-100 in bladder cancer tissues were significantly lower than those in adjacent
normal tissues (mean expression level: 2.6 ± 1.2 vs. 3.9 ± 1.5, P < 0.001). When categorized into low vs. high
expression, low miR-100 expression was negatively associated with the stage (P = 0.01), the recurrence (P = 0.008),
the progression (P = 0.01), and the death (P < 0.001) of patients with bladder cancer. Moreover, low miR-100
expression clearly predicted poorer PFS (P = 0.001) and OS (P < 0.001). In the multivariate analysis, low miR-100
expression was an independent prognostic factor for both PFS (P = 0.01) and OS (P = 0.008).
Conclusion: Our data offer the convincing evidence that miR-100 may play an important role in the progression of
bladder cancer and that the reduced expression of this miRNA may be independently associated with shorter PFS
and OS of patients, suggesting that miR-100 might be a potential marker for further risk stratification in the
treatment of this cancer.
Virtual slides: The virtual slides’ for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1105483419841671
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Bladder cancer is the seventh most common malignant
neoplasm and the eighth leading cause of cancer death
worldwide, with an estimated 68,810 new cases and
14,100 deaths in the USA in 2008 alone [1,2]. This ma-
lignancy affects the lining of the urinary bladder with a
complicated, multifactorial etiology, involving both* Correspondence: wangshenganhui@126.com
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reproduction in any medium, provided the orgenetic and environmental factors. There are two princi-
pal forms of bladder cancers: low-grade superficial
tumors and high-grade invasive cancer. The former are
often papillary and multifocal, occasionally progress to
invasive disease, and have a good prognosis, while the
latter are usually nodular, metastasize during the early
phase, and have a poor prognosis [3,4]. Approximately
70% of the patients who are diagnosed initially with
superficial bladder cancer do not face a life-threatening
situation; however, up to 70% of these patients develop-
ing at least one recurrence within 5 years [5]. Thus, thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Clinicopathologic characteristics of 126 patients
with bladder cancer ð―X  sÞ
Clinical features N (%)




























TUR; transurethral resection; LMP: low malignant potential; LG: low grade; HG:
high grade; Carcinoma in situ (CIS): 2 isolated CIS and 14 concomitant CIS.
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in spite of the considerable progress made in the treat-
ment of this disease. The challenges for controlling blad-
der cancer are the prevention of the recurrent disease
and the inhibition of the disease progression during the
treatment course. Clinicopathological parameters such
as tumor grade and stage have been used clinically to
evaluate pathologic events of bladder cancer; however,
their sensitivity is relatively low [6]. Accumulating stud-
ies have found different marker expression in this can-
cer. For example, Bahadir et al. [7] indicated that CD10
expression may be strongly correlated with high tumor
grade and stage in urothelial carcinoma of the bladder,
and that CD10 may be associated with tumor progres-
sion in bladder cancer pathogenesis; Yildiz et al. [8]
found that dual staining by p53 + CK20 cocktail may
allow for histologic correlation and diminish the risk of
losing the area of interest in limited biopsy specimens.
Therefore, identification of novel effective molecular
markers is of great significance for the improvement of
diagnostic and prognostic techniques, and for the devel-
opment of more efficient therapeutic strategies for
patients with bladder cancer.
MicroRNAs (miRNAs), small non-coding, single
strand RNA molecules that negatively regulate gene ex-
pression at the post-transcriptional level [9]. MiRNAs
can downregulate gene expression by inducing the deg-
radation or impairing the translation of target mRNAs
[10]. A single miRNA may regulate hundreds of target
mRNAs that are frequently grouped in a specific bio-
logical pathway. In the current estimate, about 900
unique miRNAs are encoded in the human genome, in
part controlling the expression of more than a third of
human genes [11]. Accumulating studies have demon-
strated that miRNAs play important roles in angiogenic
signaling, cell proliferation, apoptosis avoidance, and
tumor invasion pathways [12]. In this context, miRNAs
have been identified as promising alternative biomarkers
for detecting cancer, informing prognosis, and monitor-
ing treatment response. Recent studies have found that
more than 40 miRNAs are involved in the tumorigenesis
and tumor progression of urological cancers [13]. Many
researchers have studied miRNA expression in bladder
cancer by using various gene expression profiling
approaches. Song et al. [14] in 2010 performed the
miRNA microarray analysis with 25 cases of bladder
cancers and adjacent normal bladder tissues. They iden-
tified a panel of 51 differentially expressed miRNAs with
at least 2-fold differences in expression compared with
the normal controls, including 20 up-regulated and 31
down-regulated miRNAs. In particular, miR-100 was
found to be downregulated in bladder cancer. In another
report of Oliveira et al. [15] in 2011, enforced expression
of miR-100 may inhibit cell growth and colonyformation of human bladder cancer 5637 cells in vitro.
However, the clinical significance of miR-100 in human
bladder cancer has not yet been elucidated. Thus, the
aim of this study was to investigate the diagnostic and
prognostic values of miR-100 in this disease.
Materials and methods
Patients and tissue samples
Our study was approved by the Ethics Committee of the
First Affiliated Hospital of Bengbu Medical College,
Xiangya Hospital, and the Third Xiangya Hospital.
Informed consent was obtained from all of the patients.
One hundred and twenty-six pairs of primary bladder
cancer and adjacent normal bladder tissues (≥ 3 cm
away from bladder cancer tissues) were collected be-
tween 2007 and 2008 from the First Affiliated Hospital
Table 2 Association between miR-100 expression and
clinicopathological parameters of bladder cancer
Clinical features N miR-100 P
Low (n = 78) High (n = 48)
Sex
Male 87 55 (63.2) 32 (36.8) 0.1
Female 39 23 (59.0) 16 (40.9)
Age (years)
≤70 55 30 (54.5) 25 (45.5) 0.08
>70 71 48 (67.6) 23 (32.4)
Stage
Ta 48 20 (41.7) 28 (58.3) 0.01
T1 46 30(65.2) 16 (34.8)
≥T2 32 28 (87.5) 4 (12.5)
Grade
LMP 32 20 (62.5) 12 (37.5) 0.2
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Third Xiangya Hospital. Of these patients, 21 patients
underwent radical cystectomy, 15 patients underwent
partial cystectomy, and 90 patients underwent trans-
urethral resection of bladder tumor (TURBT). After par-
tial cystectomy and TURBT, Pirarubicin (THP) was used
in intravesical therapy as weekly intravesical injection
beginning within 24 hours after surgery. None of the
patients had received preoperative treatment. All
patients were classified according to the 1997 UICC
TNM classification for the stage and OMS 2004 for the
grade (LMP: low malignant potential; LG: low grade;
HG: high grade). Tumor recurrence/progression was
defined based on clinical, radiological, or histological
diagnoses. The clinicopathologic characteristics of the
patients with bladder cancer are shown in Table 1.
To investigate the progression-free survival (PFS) or
the overall survival (OS), we defined a time point of
36 months. PFS was defined as the time interval between
initial surgical resection and the day of the appearance
of new metastatic lesions. OS was determined from the
date of surgery to the time of the last follow-up or
cancer-related death. All patients who died from diseases
other than bladder cancer or from unexpected events
were excluded from the case collection.
TaqMan real-time quantitative RT-PCR for miRNA
miR-100 expression in bladder cancer and adjacent nor-
mal bladder tissues was measured by real-time quantita-
tive RT-PCR analysis. Briefly, total RNA was extracted
from frozen samples using Trizol reagent (Invitrogen,
Shanghai, China) according to the users’ instruction.
RNA concentration and purity were measured using the
NanoDrop ND-1000 spectrophotometer (NanoDrop
Technologies, Houston, TX, USA). Only the samples
with the OD A260/A280 ratio close to value of 2.0,Figure 1 miR-100 expression in 126 pairs of bladder cancer and
adjacent normal bladder tissues detected by quantitative real-
time polymerase chain reaction (qRT-PCR) analysis.which indicates that the RNA is pure, were subsequently
analyzed. The miR-100 and RNU6B (as an internal
control)-specific cDNA were synthesized from total RNA
using gene-specific primers according to the TaqMan
MicroRNA assays protocol (Applied Biosystems, Foster
City, CA, USA). Each reaction included 1 × primer probe
mix (TaqMan; ABI), 1× universal PCR master mix
(TaqMan; ABI), and 200 ng of cDNA. Relative quantifica-
tion of target miRNA expression was evaluated using the
comparative cycle threshold (CT) method. Each sample
was examined in triplicate and the raw data were pre-
sented as the relative quantity of target miRNA, normal-
ized with respect to RNU6B.
Statistical analysis
The software of SPSS version 13.0 for Windows (SPSS
Inc, IL, USA) was used for statistical analysis. Data wereLG 43 26(60.5) 17(39.5)
HG 51 32(62.7) 19(37.3)
Carcinoma in situ
Yes 26 18 (69.2) 8(30.8) 0.09
No 100 60 (60.0) 40 (40.0)
Recurrence
Yes 43 36(83.7) 7 (16.3) 0.008
No 73 42 (57.5) 31(42.5)
Progression
Yes 26 20 (76.9) 6 (23.1) 0.01
No 100 58 (58.0) 42(42.0)
Death
Yes 65 62 (95.4) 3 (4.6) < 0.001
No 61 16 (26.2) 45 (73.8)
TUR; transurethral resection; LMP: low malignant potential; LG: low grade; HG:
high grade.
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analysis were performed with Fisher’s exact test for any
2 × 2 tables,Pearson χ2 test for non- 2 × 2 tables. The
Cox proportional hazards model was used to evaluate
the association of miR-100 expression with PFS and OS,
respectively, after the operation. Survival curves were
estimated based on the Kaplan-Meier method. Differ-
ences were considered statistically significant when p
was less than 0.05.Results
Reduced expression of miR-100 in bladder cancer
To determine whether its expression differed between
bladder cancer and adjacent normal bladder tissues, the
expression levels of miR-100 were detected in 126 pairs
of bladder cancer and adjacent normal bladder tissues
normalized to RNU6B. As shown in Figure 1, the ex-
pression levels of miR-100 were found to be distinctly
reduced in bladder cancer tissues compared to adjacent
normal bladder tissues. The mean level of miR-100 ex-
pression in bladder cancer tissues was 2.6 ± 1.2, which
was significantly lower on average than that in adjacent
normal bladder tissues (3.9 ± 1.5, P < 0.001, Figure 1).Table 3 Univariate analyses of various clinicopathological par
cancer
Clinical features N OS
3-year survival (%)
Sex
Male 87 34 (39.1)
Female 39 22 (56.4)
Age (years)
≤70 55 20 (36.4)
>70 71 36 (50.7)
Stage
Ta 48 30 (62.5)
T1 46 22 (47.8)
≥T2 32 4 (12.5)
Grade
LMP 32 18 (56.2)
LG 43 21 (48.8)
HG 51 17 (33.3)
Carcinoma in situ
Yes 26 16 (61.5)
No 100 40 (40.0)
miR-100
High 48 33 (68.8)
Low 78 23 (29.5)Association between miR-100 expression and
clinicopathological parameters of bladder cancer
Bladder cancer tissues expressing miR-100 at levels less
than the median expression level (2.8) were assigned to
the low expression group (mean expression value 1.8,
n = 78), and those samples with expression above the
median value were assigned to the high expression
group (mean expression value 3.9, n = 48). The miR-100
expression was associated with several clinicopathologi-
cal parameters as shown in Table 2. The bladder cancer
patients with low miR-100 expression more frequently
had the high tumor stage (P = 0.01), the tumor recur-
rence (P =0.008), the advanced tumor progression
(P = 0.01), and the death (P < 0.001) of patients with
bladder cancer.Univariate analysis of the correlation between miR-100
and the survival of patients with bladder cancer
To investigate OS or PFS, we defined a time point of
36 months. During the time study, 26 (20.6%) patients
presented a progression and 100 (79.4%) did not. In
patients who progressed, 20 (76.9%) had low miR-100
expression. The 3-year OS rates of patients who wereameters in relation to survival of patients with bladder
PFS
P 3-year survival (%) P
0.08 24 (27.6) 0.08
18 (46.2)
0.1 13 (23.6) 0.1
29 (40.8)
0.006 26 (54.2) 0.008
12 (26.1)
4 (12.5)
0.02 17 (53.1) 0.03
15 (34.9)
10 (19.6)
0.01 12 (46.2) 0.02
30 (30.0)
<0.001 26 (54.2) 0.001
16 (20.5)
Figure 2 Kaplan-Meier survival curves for bladder cancer
patients according to the expression of miR-100. (A)
Progression-free survival (PFS); (B) overall survival (OS).
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were 29.5% and 68.8%, respectively (Table 3). In univari-
ate analysis, low miR-100 expression (P < 0.001), the
stage (P = 0.006), the grade (P = 0.02), and CIS (P = 0.01)
were significant predictors of short OS (Table 3). For the
3-year PFS rates, patients with low miR-100 expression
represented 20.5% and patients without, 54.2% (Table 3).
Low miR-100 expression (P = 0.001), stage (P = 0.008),
grade (P = 0.03), and CIS (P = 0.02) were also negative
predictors of the PFS (Table 3). Figure 2 shows the OS
and PFS curves with respect of miR-100 expression.
More importantly, the prognostic value of miR-100 in
bladder cancer patients was higher than that of tumorTable 4 Multivariate analyses with the Cox log-rank test of th
OS
Hazard ratio (95% CI)
Stage 7.6 (1.2 ~ 22.3)
Grade 3.9 (1.0 ~ 10.2)
Carcinoma in situ 4.8 (1.0 ~ 12.5)
miR-100 10.1 (1.5 ~ 27.2)stage (P value for OS: <0.001 vs. 0.006; for PFS: 0.001 vs.
0.008; Table 3), grade (P value for OS: <0.001 vs. 0.03;
for PFS: 0.001 vs. 0.02; Table 3) and CIS (P value for OS:
<0.001 vs. 0.02; for PFS: 0.001 vs. 0.01; Table 3).
Multivariate analysis of prognostic variables in patients
with bladder cancer
In multivariate OS analysis, miR-100, stage, grade, and
CIS was entered into the Cox proportional hazard ana-
lysis. miR-100 expression (OR, 10.1; 95% CI, 1.5 ~ 27.2;
P = 0.008), stage (OR, 7.6, 95% CI, 1.2 ~ 22.3; P = 0.01),
grade (OR, 3.9, 95% CI, 1.0 ~ 10.2; P = 0.04) and CIS
(OR, 4.8, 95% CI, 1.0 ~ 12.5; P = 0.03) retained signifi-
cance as a prognostic factor of a short OS (Table 4).
In multivariate PFS analysis, miR-100 expression
(OR, 8.3; 95% CI, 1.3 ~ 23.7; P = 0.01), stage (OR, 6.5,
95% CI, 1.0 ~ 13.1; P = 0.02), grade (OR, 1.6, 95% CI,
0.2 ~ 3.7; P = 0.08) and CIS (OR, 3.1, 95% CI, 1.0 ~
9.6; P = 0.04) were independently significant prognostic
factors (Table 4).
Discussion
In our retrospective exploratory study, there are four
main findings as following: first, the expression levels of
miR-100 in bladder cancer tissues were significantly
lower than those in adjacent normal tissues; next, low
miR-100 expression was associated with advanced tumor
progression in bladder cancer; then, low miR-100 ex-
pression was associated with shorter PFS and OS in
bladder cancer; and finally, miR-100 was identified as an
independent prognostic marker for bladder cancer. To
our best of knowledge, this is the first study on the clin-
ical significance of miR-100 expression using a large
number of bladder cancer cases.
MiR-100, together with miR-99a and miR-99b, belongs
to the miR-100 family. It is the oldest known animal
miRNA and is extensively expressed in vertebrates [16].
Recent studies have demonstrated that the aberrant ex-
pression of miR-100 is associated with tumorigenesis
and tumor progression. Notably, the roles of miR-100 in
different cancers are quite contradictory as it can behave
either as an oncogene or a tumor suppressor gene, de-
pending on the tumor type examined. MiR-100 is down-
regulated in nasopharyngeal cancer, oral squamous cell
carcinoma, ovarian cancer, hepatocellular carcinoma,e effect on OS and PFS
PFS
P Hazard ratio (95% CI) P
0.01 6.5 (1.0 ~ 13.1) 0.02
0.04 1.6 (0.2 ~ 3.7) 0.08
0.03 3.1 (1.0 ~ 9.6) 0.04
0.008 8.3 (1.3 ~ 23.7) 0.01
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lation has been described in acute myeloid leukemia,
medulloblastomas, gastric cancer, pancreatic cancer and
prostate cancer [17-27]. Especially in bladder cancer,
both the previous studies of Oliveira et al. [15] and Song
et al. [14] found the decreased expression of miR-100 in
bladder cancer cells. In line with these findings, our data
also validated the downregulation of miR-100 in a large
number of clinical bladder cancer cases. Functionally,
the aberrant expression of miR-100 in acute myeloid
leukemia cells can promote cell proliferation and block
granulocyte/monocyte differentiation [22]. Oral squa-
mous cell carcinoma cells transfected with miR-100 may
modify the expression of a number of oncogenes includ-
ing ID1, EGR2, MMP13, and FGFR3 [18]. Henson et al.
[28] also demonstrated that miR-100 could be used
therapeutically to increase the sensitivity of oral squa-
mous cell carcinoma cells to ionizing radiation by de-
creasing the expression of the genes that confer
radioresistance. These findings raise the possibility that
miR-100 might have an important role in the develop-
ment or pathogenesis of various cancers. Similarly, our
data in the present study showed that the downregula-
tion of miR-100 may more frequently occur in bladder
cancer tissues with aggressive clinicopathological fea-
tures and poor prognosis.
Conclusion
In conclusion, our data offer the convincing evidence
that miR-100 may play an important role in the progres-
sion of bladder cancer and that the reduced expression
of this miRNA may be independently associated with
shorter PFS and OS of patients, suggesting that miR-100
might be a potential marker for further risk stratification
in the treatment of this cancer. However, the mechanism
by which miR-100 was downregulated in bladder cancer
is still unclear. This study is hypothesis generating, and
that further prospective analysis should be worth doing.
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